TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

REGADENOSON

REGADENOSON
Approved 2022-04-11
Jump to: Indications Approvals Trials Competitors Safety Patents
10
Indications
--
Phase 3 Trials
3
Years on Market

Details

Status
Discontinued
First Approved
2022-04-11
Routes
INTRAVENOUS
Dosage Forms
SOLUTION

Companies

GE HEALTHCARE Hikma GLAND MEITHEAL Baxter IMS LTD Pfizer Dr. Reddy's INDIES PHARMA Apotex ACCORD HLTHCARE Viatris EUGIA PHARMA
Active Ingredient: REGADENOSON

REGADENOSON Approval History

Loading approval history...

What REGADENOSON Treats

10 FDA approvals

Originally approved for its first indication in 2022 . Covers 10 distinct patient populations.

  • Other (10)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

REGADENOSON FDA Label Details

Pro

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

FDA Approval: ANDA215955 → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.